Cargando…

S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN

Detalles Bibliográficos
Autores principales:	Rücker, Frank G, Bullinger, Lars, Cocciardi, Sibylle, Skambraks, Sabrina, Luck, Tamara J, Weber, Daniela, Schneider, Isabelle, Corbacioglu, Andrea, Gaidzik, Verena I, Jahn, Ekaterina, Jahn, Nikolaus, Kapp-Schwoerer, Silke, Schrade, Anika, Theis, Frauke, Fiedler, Walter, Salih, Helmut R, Wulf, Gerald, Salwender, Hans, Schroeder, Thomas, Götze, Katharina S, Kindler, Thomas, Lübbert, Michael, Schlenk, Richard F, Thol, Felicitas, Heuser, Michael, Ganser, Arnold, Döhner, Hartmut, Döhner, Konstanze
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428442/ http://dx.doi.org/10.1097/01.HS9.0000967452.29390.a8

Ejemplares similares

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)
por: Agrawal, Mridul, et al.
Publicado: (2019)

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
por: Cocciardi, Sibylle, et al.
Publicado: (2019)

Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
por: Teich, Katrin, et al.
Publicado: (2021)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
por: Schlenk, Richard F., et al.
Publicado: (2020)

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
por: Hirsch, Susanne, et al.
Publicado: (2017)

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
por: Gaidzik, Verena I., et al.
Publicado: (2023)

SEURAT: Visual analytics for the integrated analysis of microarray data
por: Gribov, Alexander, et al.
Publicado: (2010)

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
por: Nagel, Gabriele, et al.
Publicado: (2017)

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
por: Schlenk, R F, et al.
Publicado: (2017)

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study
por: Schlenk, Richard F., et al.
Publicado: (2016)

Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype
por: Feurstein, Simone, et al.
Publicado: (2014)

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
por: Meyer, Tatjana, et al.
Publicado: (2019)

Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia
por: Schlenk, R. F., et al.
Publicado: (2023)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
por: Heitmann, Jonas S., et al.
Publicado: (2023)

Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers
por: Lueck, Sonja C., et al.
Publicado: (2016)

Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique
por: Owattanapanich, Weerapat, et al.
Publicado: (2021)

P416: DNA METHYLATION-BASED CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA POINTS TOWARDS KDM3B AS A 5Q HAPLOINSUFFICIENCY CANDIDATE
por: Kelly, Katherine, et al.
Publicado: (2023)

Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair
por: Herzig, Julia K., et al.
Publicado: (2017)

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
por: Jahn, Nikolaus, et al.
Publicado: (2022)

P440: ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML
por: Sollier, Etienne, et al.
Publicado: (2023)

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
por: Becker, Heiko, et al.
Publicado: (2020)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
por: Jaramillo, S, et al.
Publicado: (2017)

P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
por: Jahn, Ekaterina, et al.
Publicado: (2023)

Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)
por: Rummelt, Christoph, et al.
Publicado: (2023)

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
por: Schmutz, Maximilian, et al.
Publicado: (2023)

Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
por: Jahn, Ekaterina, et al.
Publicado: (2023)

Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
por: Jahn, Ekaterina, et al.
Publicado: (2023)

The AML-associated K313 mutation enhances C/EBPα activity by leading to C/EBPα overexpression
por: Gentle, Ian Edward, et al.
Publicado: (2021)

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
por: Schlenk, R. F., et al.
Publicado: (2019)

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA
por: Stegelmann, F., et al.
Publicado: (2022)

Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia
por: Zajac, Malgorzata, et al.
Publicado: (2017)

EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position Paper
por: Macintyre, Elizabeth, et al.
Publicado: (2020)

In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts
por: Greve, Gabriele, et al.
Publicado: (2023)

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results
por: Rücker, Frank G., et al.
Publicado: (2021)

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2013)

Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia
por: Zhai, Yanan, et al.
Publicado: (2022)

S120: MNX1-ACTIVATING ENHANCER HIJACKING EVENTS IN ACUTE MYELOID LEUKEMIA WITH DELETIONS ON CHROMOSOME 7Q
por: Riedel, Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c0mscdfv6vaomn8b9g7tig5nnd